| 1 |
Khalid HMB, Rasul A, Shah S, Abbas G, Mahmood A. Disulfide Bridged Nanoparticles of Thiolated Sodium Alginate and Eudragit RS100 for Oral Delivery of Paclitaxel: In Vitro and In Vivo Evaluation. ACS Omega 2023;8:9662-72. [PMID: 36936332 DOI: 10.1021/acsomega.3c00400] [Reference Citation Analysis]
|
| 2 |
Loo C, Traini D, Young PM, Parumasivam T, Lee W. Pulmonary delivery of curcumin and quercetin nanoparticles for lung cancer – Part 2: Toxicity and endocytosis. Journal of Drug Delivery Science and Technology 2023. [DOI: 10.1016/j.jddst.2023.104375] [Reference Citation Analysis]
|
| 3 |
Wang L, Zhao C, Lu L, Jiang H, Wang F, Zhang X. Transcytosable Peptide-Paclitaxel Prodrug Nanoparticle for Targeted Treatment of Triple-Negative Breast Cancer. Int J Mol Sci 2023;24. [PMID: 36902076 DOI: 10.3390/ijms24054646] [Reference Citation Analysis]
|
| 4 |
Salve R, Kumar P, Chaudhari BP, Gajbhiye V. Aptamer Tethered Bio-Responsive Mesoporous Silica Nanoparticles for Efficient Targeted Delivery of Paclitaxel to Treat Ovarian Cancer Cells. J Pharm Sci 2023:S0022-3549(23)00013-8. [PMID: 36669561 DOI: 10.1016/j.xphs.2023.01.011] [Reference Citation Analysis]
|
| 5 |
Pramual S, Lirdprapamongkol K, Atjanasuppat K, Chaisuriya P, Niamsiri N, Svasti J. PLGA-Lipid Hybrid Nanoparticles for Overcoming Paclitaxel Tolerance in Anoikis-Resistant Lung Cancer Cells. Molecules 2022;27. [PMID: 36500387 DOI: 10.3390/molecules27238295] [Reference Citation Analysis]
|
| 6 |
Persano F, Leporatti S. Nano-Clays for Cancer Therapy: State-of-the Art and Future Perspectives. JPM 2022;12:1736. [DOI: 10.3390/jpm12101736] [Reference Citation Analysis]
|
| 7 |
Bai YT, Zhang XQ, Chen XJ, Zhou G. Nanomedicines in oral cancer: inspiration comes from extracellular vesicles and biomimetic nanoparticles. Nanomedicine (Lond) 2022;17:1761-78. [PMID: 36647844 DOI: 10.2217/nnm-2022-0142] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 8 |
Rasel MSI, Mohona FA, Akter W, Kabir S, Chowdhury AA, Chowdhury JA, Hassan MA, Al Mamun A, Ghose DK, Ahmad Z, Khan FS, Bari MF, Rahman MS, Amran MS, Raza F. Exploration of Site-Specific Drug Targeting—A Review on EPR-, Stimuli-, Chemical-, and Receptor-Based Approaches as Potential Drug Targeting Methods in Cancer Treatment. Journal of Oncology 2022;2022:1-26. [DOI: 10.1155/2022/9396760] [Reference Citation Analysis]
|
| 9 |
Zheng C, Wang L, Gao C. pH-sensitive bovine serum albumin nanoparticles for paclitaxel delivery and controlled release to cervical cancer. Appl Nanosci. [DOI: 10.1007/s13204-022-02635-y] [Reference Citation Analysis]
|
| 10 |
Wang J, He Y, Zhang B, Lv H, Nie C, Chen B, Xu W, Zhao J, Cheng X, Li Q, Tu S, Chen X. The Efficacy and Safety of Sintilimab Combined With Nab-Paclitaxel as a Second-Line Treatment for Advanced or Metastatic Gastric Cancer and Gastroesophageal Junction Cancer. Front Oncol 2022;12:924149. [PMID: 35719979 DOI: 10.3389/fonc.2022.924149] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
